Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Compass Therapeutics (CMPX) Income towards Parent Company: 2023-2025

Historic Income towards Parent Company for Compass Therapeutics (CMPX) over the last 3 years, with Sep 2025 value amounting to -$15.8 million.

  • Compass Therapeutics' Income towards Parent Company fell 29.23% to -$15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$70.1 million, marking a year-over-year decrease of 41.55%. This contributed to the annual value of -$56.6 million for FY2024, which is 33.25% down from last year.
  • Latest data reveals that Compass Therapeutics reported Income towards Parent Company of -$15.8 million as of Q3 2025, which was up 24.92% from -$21.1 million recorded in Q2 2025.
  • Compass Therapeutics' 5-year Income towards Parent Company high stood at -$7.8 million for Q1 2023, and its period low was -$21.1 million during Q2 2025.
  • For the 3-year period, Compass Therapeutics' Income towards Parent Company averaged around -$13.5 million, with its median value being -$13.1 million (2024).
  • Data for Compass Therapeutics' Income towards Parent Company shows a maximum YoY crashed of 61.10% (in 2025) over the last 5 years.
  • Compass Therapeutics' Income towards Parent Company (Quarterly) stood at -$13.4 million in 2023, then declined by 23.55% to -$16.6 million in 2024, then declined by 29.23% to -$15.8 million in 2025.
  • Its Income towards Parent Company stands at -$15.8 million for Q3 2025, versus -$21.1 million for Q2 2025 and -$16.6 million for Q1 2025.